INTRODUCTION: Multidrug therapy for leprosy is currently done with dapsone, clofazimine and rifampicin. Dapsone is known to cause hemolytic anemia (HA) and this adverse event during MDT seems to be more frequent than reported. The aim of this report is to discuss and grade HA due to dapsone during MDT treatment for leprosy. METHODS: This is a retrospective study of 194 leprosy patients from a Leprosy Control Programme Unit in Vit6ria-ES, Brazil. RESULTS: HA was observed in 48 (24.7%) patients and occurred within the first 3 months in 51% of these. Mean hematocrit levels fell from 38.5 to 31.5 and hemoglobin from 12.8 to 10.3. CONCLUSION: Dapsone used in the MDT regime for leprosy decreases the hematocrit and hemoglobin levels due to a low grade hemolysis, which can result in significant anemia.
INTRODUCTION: Multidrug therapy for leprosy is currently done with dapsone, clofazimine and rifampicin. Dapsone is known to cause hemolytic anemia (HA) and this adverse event during MDT seems to be more frequent than reported. The aim of this report is to discuss and grade HA due to dapsone during MDT treatment for leprosy. METHODS: This is a retrospective study of 194 leprosypatients from a Leprosy Control Programme Unit in Vit6ria-ES, Brazil. RESULTS: HA was observed in 48 (24.7%) patients and occurred within the first 3 months in 51% of these. Mean hematocrit levels fell from 38.5 to 31.5 and hemoglobin from 12.8 to 10.3. CONCLUSION:Dapsone used in the MDT regime for leprosy decreases the hematocrit and hemoglobin levels due to a low grade hemolysis, which can result in significant anemia.
Authors: Selma Regina Penha Silva Cerqueira; Lais Sevilha Dos Santos; Elaine Faria Morelo; Agenor de Castro Moreira Dos Santos Júnior; Carlos Augusto Felipe de Sousa; Renata Trindade Gonçalves; Gunter Hans Neto; Daniel da Silva Marques; Raimunda Nonata Ribeiro Sampaio; Patrícia Shu Kurizky; Ciro Martins Gomes Journal: Rev Soc Bras Med Trop Date: 2020-06-01 Impact factor: 1.581
Authors: Alba Llibre; Martin Dedicoat; Julie G Burel; Caroline Demangel; Matthew K O'Shea; Claudio Mauro Journal: Front Immunol Date: 2021-09-23 Impact factor: 7.561